In Vitro Thrombolysis
In Vitro Thrombolysis - Related Videos
05:52
Prehospital Thrombolysis: A Manual from Berlin
0 Views •
Cited by 20 •
2013
Identification of suspected stroke in the dispatch center of the Berlin Fire Brigade prompts the deployment of a CT-equipped ambulance. If ischemic stroke is confirmed and contraindications are excluded prehospital thrombolysis is applied.
06:38
The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
0 Views •
2025
To simulate thromboembolic stroke, emboli prepared from heterologous rat blood were injected into the middle cerebral artery, followed by administration of systemic thrombolysis for recanalization. This version of the model is optimized for use in a multi-laboratory network and supports testing multiple candidate therapeutics.
06:16
Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
0 Views •
2024
In-vitro thrombolysis assays have often struggled to replicate in-vivo conditions whether in the model thrombus being digested or in the environment in which thrombolysis is occurring. Herein, we explore how coupling the Chandler loop and Real-Time Fluorometric Flowing Fibrinolysis Assay (RT-FluFF) is used for high-fidelity, ex-vivo, clot lysis monitoring.
08:25
Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
0 Views •
Cited by 21 •
2020
This procedure was established to be used for developing advanced 3D hepatic cultures in vitro, which can provide a more physiologically relevant assessment of the genotoxic hazards associated with nanomaterial exposures over both an acute or long-term, repeated dose regimes.
08:03
An In Vitro Organ Culture Model of the Murine Intervertebral Disc
0 Views •
Cited by 22 •
2017
Whole organ culture of the intervertebral disc (IVD) preserves the native extracellular matrix, cell phenotypes, and cellular-matrix interactions. Here we describe an IVD culture system using mouse lumbar and caudal IVDs in their functional spinal units and several applications utilizing this system.
FAQs
The key biochemical sequence is activation followed by matrix breakdown: tissue plasminogen activator converts plasminogen to plasmin, and plasmin degrades fibrin. Because fibrin provides the clot’s structural scaffold, its degradation weakens clot integrity. Tracking this sequence helps determine whether a treatment initiates fibrinolysis and whether dissolution proceeds effectively.
Defined clot-formation conditions create a consistent starting point for comparing treatments. If each clot is produced under specified conditions, differences in breakdown can be related more directly to the fibrinolytic agent or engineered system being tested. This control supports measurements of treatment kinetics and helps bioengineers optimize experimental designs for meaningful performance comparisons.
Fibrin is the structural scaffold that holds the clot together, so its degradation is central to interpreting dissolution. Plasmin-mediated fibrin breakdown provides a mechanistic link between thrombolytic treatment and loss of clot structure. Measuring the resulting breakdown helps connect molecular activity with functional outcomes such as improved vessel patency in an engineered model.
A typical assay first forms a clot under defined laboratory conditions, then exposes it to a thrombolytic agent or engineered system. The experiment subsequently measures clot breakdown and treatment kinetics. This sequence separates clot preparation, therapeutic exposure, and outcome assessment, allowing researchers to evaluate how effectively a candidate approach promotes dissolution under controlled conditions.
Flow platforms add an engineered vessel context for examining how clot dissolution relates to restored vessel patency. Along with measuring breakdown, they can support assessment of treatment kinetics and the performance of drug or device systems under the platform’s defined conditions. This makes them useful for bioengineering studies focused on functional restoration rather than dissolution alone.
Researchers use these assays when they need to evaluate or optimize thrombolytic therapies, engineered systems, drugs, or devices before considering broader development. The models provide controlled measurements of clot breakdown, treatment kinetics, and vessel-patency restoration. In bioengineering, those outcomes can guide the design of approaches intended to make thrombosis treatment more effective and safer.